





JLN's Domestic Resource Mobilization Collaborative

COVID-19 Vaccine Financing: A Domestic Resource Mobilization Perspective

Landscaping of COVID19 and vaccines

From production, and registration to distribution 29 April 2020


Supported by:



BILL& MELINDA GATES foundatio








Globally, as of 2:08pm CEST, 28 April 2021, there have been 148,128,030 confirmed cases of COVID-19, including 3,124,905 deaths, reported to WHO. As of 27 April 2021, a total of 961,231,417 vaccine doses have been administered.

Global Situation Overview (as of 27 April 2021)

- Previous 24 hours:
 - 534,598 new confirmed cases.
 - 7,259 new deaths.
- Cumulative:
 - 147,377,159 confirmed cases.
 - 3,112,041 deaths.




Countries with the highest number of new cases in previous 24 hours

Country		New Cases	Total Cases	New Deaths	Total Deaths
India		323,144	17,636,307	2,771	197,894
Turkey		38,553	4,629,969	347	38,358
United States of America	-^	34,469	31,742,914	302	566,842
Brazil	m	32,572	14,340,787	1,305	390,797
France	-h	22,849	5,413,036	153	102,184
Iran (Islamic Republic of)		21,026	2,417,230	496	70,070
Colombia	m	17,190	2,774,464	465	71,351
Argentina	m	15,012	2,860,884	170	61,644
Italy	m	13,157	3,962,674	217	119,238
Germany	~~~	11,907	3,299,325	60	81,624

Number of cases

COVID19 vaccine roll out globally




Globally, as of 2:08pm CEST, 28 April 2021, there have been 148,128,030 confirmed cases of COVID-19, including 3,124,905 deaths, reported to WHO. As of 27 April 2021, a total of 961,231,417 vaccine doses have been administered.

From production, registration, planning, funding to distribution

The long road to vaccination Ensuring equitable distribution to the last mile requires specific interventions at

Delivery of COVID19 vaccines presents challenges unprecedented in scale, speed and specificities




NDVPs and WHO/WBG Readiness Assessment: 10 Core Areas of Assessments

- 1. Planning & Coordination
- 2. Resources & Funding
- 3. Regulation
- 4. Prioritization, Targeting & Surveillance
- 5. Service Delivery
- 6. Training & Supervision
- 7. Monitoring & Evaluation
- 8. Cold Chain & Logistics
- 9. Safety Surveillance
- 10. Demand Generation & Communication

R&D Pipeline (14 April)

184




Manufacturer/ Developer	Vaccine Type	Common Name	Brand Name
Pfizer/BioNTech	mRNA	Tozinameran-COVID-19 mRNA Vaccine	COMINARTY®
AZ/Serum Institute of India	Viral Vector	COVID-19 Vaccine (ChAdOx1-S ([recombinant])	COVISHIELD™
AZ/SK Bioscience	Viral Vector	COVID-19 Vaccine (ChAdOx1-S ([recombinant])	None
Janssen (J&J)	Viral Vector	COVID-19 Vaccine (Ad26.COV2-S [recombinant])	None
*Univ of Oxford/AZ	Viral Vector	COVID-19 Vaccine (ChAdOx1-S ([recombinant])	*Vaxzevria

*same COVID-19 vaccine approved by EMA was WHO EUListed on 15 April with alternative manufacturing sites as follows: Catalent Anagni (Italy), CP Pharmaceuticals (UK), IDT Biologika (Germany) and SK Bio (Rep of Korea)

	Developer/ Manufacturer	Timeline to issue decision
	Sinopharm/Beijing Institute-	End April 2021
	Sinovac	May 2021
Under review	Gamaleya	Under review, No date yet, to be confirmed Joint inspection with EMA in May or June
	Cansino	No date yet, to be confirmed
	Moderna	End of April
	Novavax	Under review No date yet.


WHO EUListed

Production by type of vaccines



Inequity is decreasing, but high income countries have administered 100x more doses per inhabitant than the lowest income countries

Cumulative COVID-19 doses administered per 100 population




ACT accelerator ACCESS TO COVID-19 TOOLS Howee by @bound



SOURCE: Our World in Data (Dec-Feb); WHO Dashboard (Mar onwards); source for income groups: World Bank. Using the latest available values for each month.

WPRO COVID-19 Vaccine Access and Availability



Note: Except for Sinovac, manufacturers in China do not disclose the no. of doses supplied to CHN. Data as of 28. 4. 2021

COVAX Allocation Overview

COVAX announced 3rd allocation round on Monday (14m doses Pfizer)

	Round #1	Round #2	Round #3
Announced	3 February	2 March	12 April
Period	February-March	January-May	April-June
Vaccine & Number of doses	Pfizer 1.2M doses	SII & AZ/SK Bio 237M doses	Pfizer 14M doses
Number of participants	18 participants	142 participants: 60 SII; 82 AZ/SK Bio	47 participants

Pfizer (3rd round) Doses for WPR Countries (April to June)

Country	Doses Allocated
Australia	15%
Lao PDR	3%
Mongolia	3%
Philippines	68%
New Zealand (SFP)	3%
Republic of Korea (SFP/UNICEF)	9%
Total	Nearly 3,5 mil doses